Sustainability Management & Value Creation - Daiichi Sankyo defines sustainability management as contributing to the sustainable development of society through innovative pharmaceutical products [19] - Three key elements drive Daiichi Sankyo's value creation: Science & Technology, Human Resources, and Patient Centricity [20] - The company aims to enhance corporate value by strengthening human and intellectual capital [8] - Daiichi Sankyo is integrating sustainability initiatives based on double materiality into the 6th Medium-Term Business Plan [92] Human Capital & Innovation - Daiichi Sankyo is strengthening Science & Technology talent through recruitment, reskilling programs, and investments in research facilities [23, 25] - The company is driving company-wide transformation through advanced digital technologies with Project 4D [25] - Innovation, robust pipelines, and global challenge opportunities fuel the continuous attraction and development of top talent [27] Patient Centricity - Daiichi Sankyo is embedding Patient Centricity across the group through internal communications, training programs, and engagement with patient groups [37, 65] - The company is promoting patient-focused drug development (PFDD) to incorporate patient voices into the drug development process [66] - Daiichi Sankyo collaborates globally with over 900 patient advocacy groups annually [66] - Daiichi Sankyo Brazil (DSBR) and American Regent (ARI) collaborated to deliver antidotes to Brazil within four days to support patients with poisoning symptoms [44]